Zelluna Immunotherapy, the company pioneering allogeneic TCR based Natural Killer (TCR-NK) cells for the treatment of cancer, announces a research collaboration agreement with Lion TCR (Singapore). The collaboration will focus on the development of TCR-NK products for the treatment of virally induced cancers.
Zelluna Immunotherapy, the company pioneering allogeneic TCR based Natural Killer (TCR-NK) cells for the treatment of cancer, announces a research collaboration agreement with Lion TCR (Singapore). The collaboration will focus on the development of TCR-NK products for the treatment of virally induced cancers.